|
NEW RESEARCH MARKS IMPORTANT STEP FORWARD IN UNDERSTANDING REAL-WORLD USE OF PREP
19 July 2016 - Durban, South Africa – Several studies presented today in an official press conference at the 21 st International AIDS Conference (AIDS 2016) in Durban provided new insights on the use of PrEP among a broad range of populations. One study provided new national estimates of PrEP use in the U.S. by geography and other demographics, another found the near elimination of HIV transmission risk among serodiscordant heterosexual couples using both PrEP and antiretroviral treatment, and two additional studies examined PrEP use among adolescents in both southern Africa and the U.S.
“Just as the 2000 International AIDS Conference in Durban ushered in a global movement to bring life-saving HIV treatment to the developing world, I am confident we'll look back at this conference as the dawn of the global PrEP era,” said Linda-Gail Bekker, President-elect of the International AIDS Society and Principal Investigator at the Desmond Tutu HIV Centre. “A primary focus of this conference is moving science into practice, and nowhere is that need more urgent than for PrEP.”
Research featured in the briefing included:
Increased PrEP use among U.S. adults: A nationally representative study assessing PrEP use in the U.S. found that 49,469 adults received a Truvada prescription for PrEP from January 2013 to December 2015, and that the number of prescriptions increased nationally over time: 3,746 in 2013; 14,756 in 2014; and 30,967 in 2015. Scott McCallister of Gilead Sciences, Inc., the manufacturer of Truvada, presented the study, which included de-identified data from 82% of retail pharmacies on adults who received a Truvada prescription. Study results also showed that the four states with the highest number of new HIV cases in the U.S. (California, New York, Texas, and Florida) accounted for 43% of PrEP starts. From 2014 to 2015, PrEP starts increased in the South and Northeast, and decreased in the Midwest and West. The vast majority of PrEP prescriptions were for males (87.5%), and the mean age was 37.4 years, with 11.5% under age 25. Compared to HIV-positive individuals, those receiving PrEP were about three times less likely to be female (95% CI 3.0-3.2) and twice as likely to be under age 25 (95% CI 1.93-2.05). Despite positive trends in utilization, authors conclude that PrEP use must increase to ensure that lifetime HIV risk decreases in areas of high prevalence in the U.S. [Summary based on submitted abstract; updated data may be presented on site.]
- Abstract: Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: (2013-2015)
- Session: Latebreaker Session (Session Room 6, Tuesday 19 July 13:00-14:00 SAST)
Combination of PrEP and ART leads to near elimination of HIV transmission among serodiscordant couples: Final results from the Partners Demonstration Project, an open-label PrEP and ART delivery study that enrolled treatment-naïve, high-risk, heterosexual HIV serodiscordant couples from Kenya and Uganda, found that integrated use of PrEP and ART nearly eliminated HIV transmission within these couples. Of 1,013 couples enrolled, 67% had an HIV-positive female partner; median age was 29. Among a randomly selected sample of HIV-negative partners receiving PrEP, tenofovir was detected in 82% of plasma samples (483/587 visits). Treatment was initiated by 92% of HIV-positive partners by 24 months, and viral suppression (<400 copies/mL) was achieved in 90%. As of January 2016, scientific models predicted that 63 incident HIV infections would be expected (incidence rate 5.1 per 100 person years, 95% CI 3.9-6.4). However, Jared Baeten of the University of Washington reported that only 5 incident infections had actually been observed (incidence rate 0.3, 95% CI 0.1-0.7), for a sustained HIV relative risk reduction of 94% (95% CI 85-98, p<0.001). The results show near elimination of HIV risk among a high-risk cohort. [Summary based on submitted abstract; updated data may be presented on site.]
- Abstract: Integrated delivery of PrEP and ART results in sustained near elimination of HIV transmission in African HIV serodiscordant couples: final results from the Partners Demonstration Project
- Session: Making PrEP Real for Those Who Need It Most: Optimization Strategies (Session Room 1, Wednesday 20 July 11:00-12:30 SAST)
Closer look at PrEP use among adolescents at risk: Plus Pills is the first southern African open-label study to explore the acceptability, safety, and use of oral PrEP among HIV-negative adolescents (ages 15-19 years). Study participants (n=148; 98 female and 50 male) enrolled in two sites, Cape Town and Soweto. Median age of study participants was 18 and median age at sexual debut was 15. Participants were required to take PrEP daily for the first 12 weeks of the study, but could opt out at the 12-week mark and at each 3-month interval thereafter. At enrolment, participants reported an average of 1.5 weekly sex acts, 30% had two or more partners in the past 12 months, 43% reported infrequent condom use, and 38% tested positive for sexually transmitted infections. Lead author Katherine Gill of the Desmond Tutu HIV Centre discussed the study results, which found no HIV incident infections. At 12 weeks, 72% reported good adherence (>6 pills/week) and 76% had tenofovir plasma levels (>40 ng/ml). At the 12-week mark, 15% of participants chose to opt out. According to study authors, results showed that early adherence was reasonable among a high-risk adolescent population. [Summary based on submitted abstract; updated data may be presented on site.]
- Abstract: An analysis of baseline and early data from the Plus Pills study: an open-label trial of pre-exposure prophylaxis for South African adolescents
- Session: Poster Exhibition (Upper Level, Tuesday 19 July 12:30-14:30 SAST)
A separate open-label study looked at PrEP use among gay and bisexual male adolescents (ages 15-17) in six U.S. cities. While Truvada is not currently licensed for PrEP among individuals under age 18, participants were permitted to autonomously consent to the study. Between August 2013 and September 2014, ATN 113 (Project PrEPare) enrolled 78 individuals (mean age=16.5; 33.3% mixed race, 29.5% black, 20.5% Latino). Sybil Hosek of the Stroger Hospital of Cook County Health and Hospitals System presented the study results. Incident sexually transmitted infections were diagnosed in 12.3% of participants at week 24 and 10.6% at week 48. The HIV seroconversion rate per 100 person-years was 6.41 (95% CI: 4.90-25.87). The majority of participants reported condomless sex throughout the study; no significant associations were found between condomless sex and adherence. While the majority of participants achieved protective drug levels during monthly visits, the study found that adherence decreased with quarterly visits. [Summary based on submitted abstract; updated data may be presented on site.]
- Abstract: An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for adolescent MSM ages 15-17 in the United States
- Session: Latebreaker Session (Session Room 6, Tuesday 19 July 13:00-14:00 SAST)
###
About the International AIDS Conference
The International AIDS Conference is the largest conference on any global health or development issue. First convened during the peak of the AIDS epidemic in 1985, this conference continues to provide a unique forum for the intersection of science and advocacy, and an opportunity to strengthen policies and programmes to ensure an evidence-based response to the epidemic. The conference also serves as a focal point to intensify political and financial commitments to AIDS. The 21st International AIDS Conference (AIDS 2016) is being held in Durban, South Africa (18-22 July 2016).
AIDS 2016 Conference Organizers
AIDS 2016 is organized by the International AIDS Society in partnership with the Global Network of People Living with HIV (GNP+); the International Council of AIDS Service Organizations (ICASO); the International Community of Women Living with HIV/AIDS (ICW Global), and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Non-permanent partners are ICW Eastern Africa and the Men who Have Sex with Men Global Forum (MSMGF). Local partners are the South Africa National AIDS Council, the Department of Health for the Republic of South Africa, and the South African Medical Research Council (SAMRC). Regional partners are the AIDS Rights Alliance for Southern Africa (ARASA), Enda Santé, and Réseau Africain des Praticiens Assurant la Prise en Charge Médicale des Personnes Vivant avec le VIH/SIDA (RESAPSI).
About the International AIDS Society
Founded in 1988, the International AIDS Society (IAS) is the world’s largest association of HIV professionals, with members from more than 180 countries. IAS members work on all fronts of the global response to AIDS and include researchers, clinicians, policy and programme planners, and public health and community practitioners.
Media Contact:
Mandy Sugrue,
+27.62.295.4205
Mandy.Sugrue@iasociety.org
AIDS 2016: Join the Conversation
Get the latest conference updates and share your thoughts and ideas through the AIDS 2016 social media channels.
- Tweet along with us – @AIDS_conference and @iasociety – using #AIDS2016 to keep the conversation going.
- Like AIDS 2016 on Facebook – and stay in touch with the latest conference updates and developments.
- Check us out on Instagram to see photos as they are happening.
Visit our YouTube channel to see featured videos and other content.
"Reproduced with permission - International AIDS Society"
International AIDS Society
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
